Skip to main content
SpringerLink
Log in

What Are the Complications of Home IBD Medications?

  • Chapter
  • First Online:
Gastrointestinal Emergencies

  • 79 Accesses

Abstract

Inflammatory bowel disease may be treated with a variety of medications depending on the severity of disease, location of disease, and goals of treatment. Common medications include systemic and local glucocorticoids, antibiotics, 5-aminosalicylates, immunomodulatory agents, and biologic therapies. Each medication class carries distinct and important side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Curtis J. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–6.

    Article  Google Scholar 

  2. Etminan M. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology. 2014;83(14):1261.

    Article  CAS  Google Scholar 

  3. Khaliq Y. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404.

    Article  Google Scholar 

  4. Kang J. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122–6.

    Article  CAS  Google Scholar 

  5. Carroll M. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3903–9.

    Article  CAS  Google Scholar 

  6. Deshpande A. Community-associated clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951.

    Article  CAS  Google Scholar 

  7. Box SA. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol. 1997;36(3):382–6.

    Article  CAS  Google Scholar 

  8. Farr M. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs. 1986;32(Suppl 1):49–53.

    Article  Google Scholar 

  9. Schroeder K. Is mesalamine safe? Gastroenterol Hepatol (NY). 2007;3(11):878–9.

    Google Scholar 

  10. Chaparro M. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19(7):1404–10.

    Article  Google Scholar 

  11. Beaugerie L. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.

    Article  CAS  Google Scholar 

  12. Te HS. Hepatic effects of long-term methotrexate use in treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95(11):3150.

    Article  CAS  Google Scholar 

  13. Burdmann EA. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465–76.

    Article  CAS  Google Scholar 

  14. Hoorn EJ. The cacineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17(10):1304–9.

    Article  CAS  Google Scholar 

  15. Eidelman BH. Neurologic complications of FK 506. Transplant Proc. 1991;23(6):3175–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994;344(8920):423–8.

    Google Scholar 

  17. Hojo M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4.

    Article  CAS  Google Scholar 

  18. Strangfield A. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914–20.

    Article  Google Scholar 

  19. Cheifetz A. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenerol. 2003;98(6):1315–24.

    Article  CAS  Google Scholar 

  20. Hastings R. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62(6):764.

    Article  Google Scholar 

  21. Cleynen I. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22.

    Article  Google Scholar 

  22. Gabriel SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum. 2008 Mar;58(3):637–40.

    Article  Google Scholar 

  23. Dreyer L. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish multiple sclerosis registry. Ann Rheum Dis. 2016;75(4):785–6.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MedStar Georgetown University and Washington Hospital Center, Washington, DC, USA

    Kathryn Voss

Authors
  1. Kathryn Voss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathryn Voss .

Editor information

Editors and Affiliations

  1. Department of Emergency Medicine, MedStar Georgetown University Hospital, Washington, DC, USA

    Autumn Graham

  2. Department of Emergency Medicine, MedStar Georgetown University Hospital, Washington, DC, USA

    David J. Carlberg

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Voss, K. (2019). What Are the Complications of Home IBD Medications?. In: Graham, A., Carlberg, D.J. (eds) Gastrointestinal Emergencies. Springer, Cham. https://doi.org/10.1007/978-3-319-98343-1_90

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98343-1_90

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98342-4

  • Online ISBN: 978-3-319-98343-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation